The clinical heterogeneity of coenzyme Q<subscript>10</subscript> deficiency results from genotypic differences in the Coq9 gene.

Primary coenzyme Q 10 (CoQ 10 ) deficiency is due to mutations in genes involved in CoQ biosynthesis. The disease has been associated with five major phenotypes, but a genotype-phenotype correlation is unclear. Here, we compare two mouse models with a genetic modification in Coq9 gene ( Coq9 Q95X and Coq9 R239X ), and their responses to 2,4-dihydroxybenzoic acid (2,4-di HB). Coq9 R239X mice manifest severe widespread CoQ deficiency associated with fatal encephalomyopathy and respond to 2,4-di HB increasing CoQ levels. In contrast, Coq9 Q95X mice exhibit mild CoQ deficiency manifesting with reduction in CI+ III activity and mitochondrial respiration in skeletal muscle, and late-onset mild mitochondrial myopathy, which does not respond to 2,4-di HB. We show that these differences are due to the levels of COQ biosynthetic proteins, suggesting that the presence of a truncated version of COQ9 protein in Coq9 R239X mice destabilizes the CoQ multiprotein complex. Our study points out the importance of the multiprotein complex for CoQ biosynthesis in mammals, which may provide new insights to understand the genotype-phenotype heterogeneity associated with human CoQ deficiency and may have a potential impact on the treatment of this mitochondrial disorder. [ABSTRACT FROM AUTHOR]

Copyright of EMBO Molecular Medicine is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)